GS7.F: Summary for GLAXOSMITHKLINE LS-,25 - Yahoo Finance

UK Markets closed

GlaxoSmithKline plc (GS7.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
18.93-0.16 (-0.81%)
At close: 7:07PM CEST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous close19.08
Bid18.64 x 110000
Ask18.91 x 110000
Day's range18.57 - 18.93
52-week range16.92 - 20.57
Avg. volume5,283
Market cap90.75B
PE ratio (TTM)81.58
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View
    Zacks2 hours ago

    Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View

    GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with the Zacks Consensus Estimate.

  • hours ago

    Last chance to buy GlaxoSmithKline plc for under £16?

    Is now the perfect time to buy a stake in GlaxoSmithKline plc (LON:GSK)?

  • Reutersyesterday

    New GlaxoSmithKline CEO wants fewer, bigger new drug launches

    GlaxoSmithKline's new chief executive aims to improve returns in drug development, and wants fewer but bigger new medicine launches. In her first comments since taking over on April 1, Emma Walmsley, 47, said on Wednesday that her priority was the pharmaceuticals unit, where she wants commercial considerations to be given greater weight in early investment decisions. "We'd like to have probably fewer and more focused priorities, to have bigger launches," she told reporters, after announcing first-quarter results, adding this would involve tough choices and the closure of some research programmes.